TY - JOUR
T1 - Utilization of stem cells to treat congenital heart disease
T2 - Hype and hope
AU - Peral, Susana Cantero
AU - Burkharte, Harold M.
AU - Nelsona, Timothy J.
N1 - Publisher Copyright:
© 2014 Wolters Kluwer Health-Lippincott Williams & Wilkins.
PY - 2014
Y1 - 2014
N2 - Purpose of review Surgical advances over the past few decades have transformed the clinical management of congenital heart disease, such as hypoplastic left heart syndrome. Congenital heart disease affects more than 1% of liveborn infants and accounts for more than 2.5 million affected children per year worldwide. The cost and availability of complex medical management for these children becomes bluntly realized when heart failure progresses and only palliative options remain. Cell-based cardiac regeneration has been the focus of intensive efforts in adult heart disease for more than a decade and now has promise for pediatrics. Recent findings Innate cardiac regeneration in the pediatric setting is measurable and potentially modifiable in the early stages of development. Repurposing cell-based manufactured products to promote cardiac regeneration in congenital heart disease has demonstrated significant improvement in cases of dilated cardiomyopathy and structural heart disease in infants. Summary A focus on preemptive cardiac regeneration in the pediatric setting may offer new insights into the timing of surgery, location of cell-based delivery, and type of cell-based regeneration that could further inform acquired cardiac disease applications. The concept of cell-based pediatric cardiac regenerative surgery could transform the management of congenital heart disease when cost-effective strategies produce a valuable adjunctive solution to improve outcomes of cardiac surgery.
AB - Purpose of review Surgical advances over the past few decades have transformed the clinical management of congenital heart disease, such as hypoplastic left heart syndrome. Congenital heart disease affects more than 1% of liveborn infants and accounts for more than 2.5 million affected children per year worldwide. The cost and availability of complex medical management for these children becomes bluntly realized when heart failure progresses and only palliative options remain. Cell-based cardiac regeneration has been the focus of intensive efforts in adult heart disease for more than a decade and now has promise for pediatrics. Recent findings Innate cardiac regeneration in the pediatric setting is measurable and potentially modifiable in the early stages of development. Repurposing cell-based manufactured products to promote cardiac regeneration in congenital heart disease has demonstrated significant improvement in cases of dilated cardiomyopathy and structural heart disease in infants. Summary A focus on preemptive cardiac regeneration in the pediatric setting may offer new insights into the timing of surgery, location of cell-based delivery, and type of cell-based regeneration that could further inform acquired cardiac disease applications. The concept of cell-based pediatric cardiac regenerative surgery could transform the management of congenital heart disease when cost-effective strategies produce a valuable adjunctive solution to improve outcomes of cardiac surgery.
KW - Congenital heart disease
KW - Hlhs
KW - Hypoplastic left heart syndrome
KW - Regenerative medicine
KW - Stem cell therapy
UR - http://www.scopus.com/inward/record.url?scp=84928209221&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928209221&partnerID=8YFLogxK
U2 - 10.1097/MOP.0000000000000138
DO - 10.1097/MOP.0000000000000138
M3 - Review article
C2 - 25117663
AN - SCOPUS:84928209221
SN - 1040-8703
VL - 26
SP - 553
EP - 560
JO - Current opinion in pediatrics
JF - Current opinion in pediatrics
IS - 5
ER -